Kaiser Westside Medical Center
- Type
- Teaching hospital
- Where
- Hillsboro, OR
- Medicare CCN
- 380103
- Received
- $777,062 in 31 records, 2022 ($0 general, $777,062 research)
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2022 | Research payment | 31 | $777,062 |
By company
| Company | Records | Amount | Years |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | 4 | $506,646 | 2022 |
| Eli Lilly and Company | 13 | $131,945 | 2022 |
| E.R. Squibb & Sons, L.L.C. | 1 | $69,843 | 2022 |
| Janssen Research & Development, LLC | 2 | $29,457 | 2022 |
| Intercept Pharmaceuticals, Inc. | 5 | $24,281 | 2022 |
| AstraZeneca Pharmaceuticals LP | 5 | $14,374 | 2022 |
| Merck Sharp & Dohme LLC | 1 | $514 | 2022 |
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 31 | $777,062 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2022-12-31 | AstraZeneca Pharmaceuticals LP | $870 | Research payment | In-kind items and services | TAGRISSO Drug, Oncology | To assess the efficacy and safety of AZD9291 versus Placebo in patients with Epidermal Growth Factor Receptor Mutation P | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $514 | Research payment | In-kind items and services | Biological, INFECTIOUS DISEASE | A Phase 1,Phase 2, Randomized, Double-blind Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Polyvale | 2022 |
| 2022-12-31 | AstraZeneca Pharmaceuticals LP | $313 | Research payment | In-kind items and services | IMFINZI Biological, Oncology | A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of Durvalumab Monotherapy or in Combinatio | 2022 |
| 2022-12-30 | Janssen Scientific Affairs, LLC | $101,329 | Research payment | Cash or cash equivalent | SPRAVATO Drug, Neuroscience | 2022 | |
| 2022-12-26 | Janssen Scientific Affairs, LLC | $227,990 | Research payment | Cash or cash equivalent | SPRAVATO Drug, Neuroscience | 2022 | |
| 2022-12-12 | Janssen Research & Development, LLC | $11,661 | Research payment | Cash or cash equivalent | A Phase 3, Open-Label, Randomized Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Co | 2022 | |
| 2022-09-27 | Eli Lilly and Company | $768 | Research payment | In-kind items and services | THE EFFECT OF TIRZEPATIDE VERSUS DULAGLUTIDE ON MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES (SU | 2022 | |
| 2022-09-22 | Eli Lilly and Company | $35 | Research payment | In-kind items and services | EMBER-4: A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ADJUVANT IMLUNESTRANT VS STANDARD ADJUVANT ENDOCRINE THERAPY IN PATI | 2022 | |
| 2022-09-14 | Janssen Research & Development, LLC | $17,796 | Research payment | Cash or cash equivalent | A Phase 3, Open-Label, Randomized Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Co | 2022 | |
| 2022-07-20 | Intercept Pharmaceuticals, Inc. | $150 | Research payment | Cash or cash equivalent | Study Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic | 2022 | |
| 2022-07-18 | Eli Lilly and Company | $14,310 | Research payment | Cash or cash equivalent | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICI | 2022 | |
| 2022-07-13 | Intercept Pharmaceuticals, Inc. | $7,840 | Research payment | Cash or cash equivalent | Study Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic | 2022 | |
| 2022-06-22 | Intercept Pharmaceuticals, Inc. | $11,604 | Research payment | Cash or cash equivalent | Study Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic | 2022 | |
| 2022-06-14 | Eli Lilly and Company | $24,801 | Research payment | Cash or cash equivalent | EMONARCHER: A RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY OF ABEMACICLIB PLUS STANDARD ADJUVANT ENDOCRINE | 2022 | |
| 2022-05-26 | E.R. Squibb & Sons, L.L.C. | $69,843 | Research payment | Cash or cash equivalent | OPDIVO Biological, Oncology | A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks i | 2022 |
| 2022-05-25 | Eli Lilly and Company | $18,641 | Research payment | Cash or cash equivalent | EMBER-3: A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF LY3484356 VS INVESTIGATOR'S CHOICE OF ENDOCRINE THERAPY, IN PATIENTS | 2022 | |
| 2022-04-15 | AstraZeneca Pharmaceuticals LP | $6,735 | Research payment | Cash or cash equivalent | TAGRISSO Drug, Oncology | To assess the efficacy and safety of AZD9291 versus Placebo in patients with Epidermal Growth Factor Receptor Mutation P | 2022 |
| 2022-04-07 | Eli Lilly and Company | $8,343 | Research payment | Cash or cash equivalent | A PHASE 1/2 STUDY OF ORAL SELPERCATINIB (LOXO-292) IN PATIENTS WITH ADVANCED SOLID TUMORS, INCLUDING RET FUSION-POSITIVE | 2022 | |
| 2022-04-05 | Janssen Scientific Affairs, LLC | $75,997 | Research payment | Cash or cash equivalent | SPRAVATO Drug, Neuroscience | 2022 | |
| 2022-03-23 | Intercept Pharmaceuticals, Inc. | $3,459 | Research payment | Cash or cash equivalent | Study Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic | 2022 | |
| 2022-03-23 | Intercept Pharmaceuticals, Inc. | $1,227 | Research payment | Cash or cash equivalent | Study Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic | 2022 | |
| 2022-02-10 | AstraZeneca Pharmaceuticals LP | $1,500 | Research payment | In-kind items and services | IMFINZI Biological, Oncology | A Phase 2 Open-label, Multicenter, Randomized, Multidrug Platform Study of Durvalumab (MEDI4736) Alone or in Combination | 2022 |
| 2022-02-08 | Janssen Scientific Affairs, LLC | $101,330 | Research payment | Cash or cash equivalent | SPRAVATO Drug, Neuroscience | 2022 | |
| 2022-02-08 | Eli Lilly and Company | $12,765 | Research payment | Cash or cash equivalent | A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ABEMACICLIB COMBINED WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD | 2022 | |
| 2022-02-03 | Eli Lilly and Company | $1,360 | Research payment | In-kind items and services | THE EFFECT OF TIRZEPATIDE VERSUS DULAGLUTIDE ON MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES (SU | 2022 | |
| 2022-01-31 | Eli Lilly and Company | $9,360 | Research payment | In-kind items and services | A PHASE 2, RANDOMIZED, PARALLEL, OPEN-LABEL COMPARATOR CONTROLLED TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF LY3209590 | 2022 | |
| 2022-01-26 | AstraZeneca Pharmaceuticals LP | $4,955 | Research payment | Cash or cash equivalent | IMFINZI Biological, Oncology | A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of Durvalumab Monotherapy or in Combinatio | 2022 |
| 2022-01-26 | Eli Lilly and Company | $3,004 | Research payment | In-kind items and services | THE EFFECT OF TIRZEPATIDE VERSUS DULAGLUTIDE ON MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES (SU | 2022 | |
| 2022-01-14 | Eli Lilly and Company | $220 | Research payment | In-kind items and services | EMBER-3: A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF LY3484356 VS INVESTIGATOR'S CHOICE OF ENDOCRINE THERAPY, IN PATIENTS | 2022 | |
| 2022-01-07 | Eli Lilly and Company | $24,469 | Research payment | Cash or cash equivalent | A PHASE 1/2 STUDY OF ORAL SELPERCATINIB (LOXO-292) IN PATIENTS WITH ADVANCED SOLID TUMORS, INCLUDING RET FUSION-POSITIVE | 2022 | |
| 2022-01-07 | Eli Lilly and Company | $13,869 | Research payment | Cash or cash equivalent | A PHASE 1/2 STUDY OF ORAL SELPERCATINIB (LOXO-292) IN PATIENTS WITH ADVANCED SOLID TUMORS, INCLUDING RET FUSION-POSITIVE | 2022 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Hillsboro, OR, county Washington County, OR, state Oregon; placed by its city name.
| Measure | Place (city or town) Hillsboro, OR | County Washington County, OR | State Oregon |
|---|---|---|---|
| Population B01003 | 108,231 | 603,947 | 4,254,293 |
| Population, 2020 census P1 | 106,447 | 600,372 | 4,237,256 |
| Median age B01002 | 35.0 | 38.1 | 40.4 |
| Under 18 B01001 | 20.4% | 21.6% | 19.9% |
| 65 and over B01001 | 11.9% | 14.8% | 19.1% |
| Households B11001 | 42,145 | 235,406 | 1,718,422 |
| Foreign born B05002 | 20.4% | 18.3% | 9.8% |
| Median household income B19013 | $106,409 | $107,772 | $83,011 |
| Median family income B19113 | $115,671 | $127,794 | $102,281 |
| Per capita income B19301 | $51,232 | $53,929 | $45,612 |
| Poverty rate B17001 | 8.5% | 8.1% | 11.9% |
| Unemployment rate B23025 | 4.8% | 4.5% | 5.4% |
| Civilian labor force B23025 | 63,315 | 335,177 | 2,183,462 |
| Mean commute (minutes) B08013 | 22.9 | 24.0 | 23.0 |
| Bachelor's degree or higher B15003 | 42.3% | 47.5% | 36.8% |
| Housing units B25001 | 43,576 | 243,278 | 1,857,992 |
| Owner-occupied B25003 | 50.2% | 60.8% | 63.3% |
| Renters B25003 | 49.8% | 39.2% | 36.7% |
| Median home value B25077 | $521,100 | $588,000 | $477,600 |
| Median gross rent B25064 | $1,978 | $1,849 | $1,525 |
| White, not Hispanic B03002 | 52.0% | 60.0% | 71.4% |
| Black B03002 | 2.9% | 2.2% | 1.8% |
| Hispanic or Latino B03002 | 25.8% | 18.6% | 14.7% |
| Asian B03002 | 11.3% | 11.4% | 4.4% |
| American Indian and Alaska Native B03002 | 0.3% | 0.3% | 0.6% |
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Hillsboro, OR.
Comments